Linkedin Youtube
Launch Digital Edition

Webinars and Sponsored Roundtables — Register Now

Wednesday, September 23, 2026. 12 PM-1 PM ET
Roundtable presenters Dr. David Sacks MB, ChB, FRCPath, Chairman, Steering Committee National Glycohemoglobin Standardization Program (NGSP), and Priya Sivaraman, PhD, Senior Technical Product Manager, Tosoh Bioscience

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, September 24, 2026 11 AM-12 PM CT
This session explores the evolving role of RAS in precision oncology, from the biology of RAS mutations to the expanding landscape of targeted therapies. Through expert presentations, real-world case discussions, and interactive audience polling, participants will examine best practices for RAS biomarker testing across solid tumors, including lung, colorectal, and pancreatic cancers. The session will highlight practical considerations for tissue and liquid biopsy, strategies to address testing gaps, and the importance of multidisciplinary collaboration to ensure timely identification of patients who may benefit from RAS-targeted therapies.

Webinar presenters David Braxton, MD, Chief of Molecular Pathology Services, Hoag Family Cancer Institute & Hoag Memorial Hospital Presbyterian, and Carlos Becerra, MD, Research Director for Medical Oncology, Margaret Given Larkin Endowed Chair for Developmental Cancer Therapeutics, Hoag Memorial Hospital Presbyterian

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Wednesday, September 30, 2026. 1 PM-1:30 PM ET
Roundtable presenters John Longshore, PhD, Head of Scientific Affairs, Global Oncology Diagnostics, AstraZeneca, and Flora Berisha, MS, Executive Director, Global Head of Diagnostic Partnering and Development, Johnson & Johnson Innovative Medicine, and Mark D. Ewalt, MD, Associate Medical Director for Laboratory Operations, Diagnostic Molecular Pathology, Molecular Diagnostics Service, Department of Pathology and Laboratory Medicine, Memorial Sloan Kettering Cancer Center, and Isabel Preeshagul, DO, MBS, Thoracic Medical Oncologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Thursday, October 1, 2026 1 PM-2 PM ET
This presentation will explore the value of in-house CGP, offer insights into the benefits and drawbacks of incorporation, and provide information about important practical factors when considering in-house implementation of CGP.

Webinar presenter Allison M. Cushman-Vokoun, MD, PhD, FCAP, Medical Director, Molecular Diagnostics and Personalized Medicine Laboratory, Director, Division of Diagnostic Molecular Pathology and Human Genetics, Henry F. Krous Professor of Pathology, University of Nebraska Medical Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Tuesday, October 20, 2026 11 AM-12 PM ET
Hear experts review the biological and clinical significance of the HER2 expression continuum in breast tissue, providing a clearer understanding of how these variations might impact diagnosis, and discuss the emerging importance of documenting HER2-low and HER2-ultralow categories using a validated IHC assay.

Webinar presenters Keith Wharton, MD, PhD, Global Medical Affairs Leader–Pathology, Roche Diagnostics Solutions, and Hannah Y. Wen, MD, PhD, Director, Breast Pathology Fellowship, Associate Team Leader, Breast Pathology Team, Attending Pathologist, Memorial Sloan Kettering Cancer Center

Moderated by: Bob McGonnagle, Publisher, CAP TODAY

Register Now

Subspecialties

Interactive Product Guides

ARTICLES

New guidance on lung cancer testing

April 2013—It was a monumental task: create a molecular testing guideline for lung cancer. Among other tasks, those involved (representing the CAP, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology) reviewed 1,533 abstracts and read, in detail, 521 full-text articles. There was extensive evidence grading; naturally, new literature was published in the interim, which required even more reviews. The payoff was the first international, evidence-based, multidisciplinary guideline for this part of lung cancer care. It contains 37 items addressing 14 subjects, including 15 recommendations (evidence grade A/B).

New attention on POC device disease transmission

April 2013—When 19th-century Hungarian obstetrician Ignaz Semmelweis found that doctors could dramatically decrease puerperal infections by washing their hands with a chlorinated lime solution before delivering babies, his colleagues thought he was nuts. Why, everyone knew that infections were caused by noxious air!

Laboratory provider links software product guide, 4/13:12

As hospitals and eligible providers work to meet the government’s 2015 deadline for implementing electronic health record systems to comply with the HITECH Act of 2009, are laboratory-provider links (LPL) software companies being left out in the cold?

In coag, all eyes on new anticoagulants and new systems, 1/13:12

The newer oral anticoagulants are top of mind not only inside coagulation labs but also for the companies committed to creating coagulation testing solutions. “The rapid introduction of the new oral anticoagulant drugs and expanded indications for existing drugs are driving an urgent need for laboratory testing in cases of unexplained bleeding and surgery,” says Diagnostica Stago’s director of marketing, Hamid Erfanian, who reports that Stago is responding with research-use-only calibrators and controls for several of these drugs to enable rapid, automated testing.

Order more tests? With diabetes, answer may be ‘yes’

March 2013—In patients with diabetes mellitus, hemoglobin A1c testing frequency is largely in line with recommended guidelines. In those same patients, LDL testing is not performed frequently enough, and urine protein testing frequency falls far short of recommendations.

Policing blood use pays off for Allina Laboratories

March 2013—A January study of almost 1,000 patients with acute gastrointestinal bleeding has found that restrictive blood transfusion strategies produce better patient outcomes. The study, “Transfusion strategies for acute upper gastrointestinal bleeding,” discovered that patients with severe acute upper GI bleeding who received blood transfusions when their hemoglobin levels fell below 7 g/dL, rather than 9 g/dL, had higher probabilities of survival at six weeks, as well as reduced rates of further bleeding and fewer adverse events (Villanueva C, et al. N Engl J Med. 2013;368:11–21).

Molecular walk-through for CRC testing

March 2013—For pathologists and clinicians alike, molecular testing can carry shades of a Pinter play: a seemingly straightforward situation with a whiff of discomfort, if not outright menace, and bedeviled by shifting characters and layers of meaning that defy snap interpretations.

What happened when lab set sights on parasites

March 2013—When Bobbi S. Pritt, MD, director of clinical parasitology and virology in the Division of Clinical Microbiology at Mayo Clinic, set out to improve test utilization among the physicians for whom her laboratory performs assays, she figured that knowledge was power. Simply educate the clinicians, she thought, and surely they would begin to order the most appropriate tests for their patients.

Houston study augurs possible shift in hrHPV genotypes

March 2013—First identified in an HIV patient in 1998, HPV 90 is a genotype of the human papillomavirus that, until now, has received little attention. It is not counted as one of the few well-defined high-risk genotypes, like HPV 16 and HPV 18, that are known to cause the majority of cervical cancer cases.

Bedside glucose testing systems product guide, 3/13:12

New to the CAP TODAY lineup of point-of-care blood glucose systems is the Roche Accu-Chek Inform II, which the FDA cleared last fall. It offers meter-level wireless technology, conducts extensive integrity checks with each test, has an advanced laser bar-code scanner, and provides up to three unique patient identifiers. An Other Test Entry feature makes it possible to capture and store results for multiple POC tests.

MARKETPLACE

TRENDING